Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer.

Next Previous
Trial Profile

The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 24 Aug 2019 Status changed from recruiting to active, no longer recruiting.
  • 03 Sep 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top